DRAPER, Utah, March 02, 2023 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced plans to release its fourth quarter and year-end fiscal 2023 financial results following the close of regular stock market trading hours on Tuesday, March 21, 2023. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, March 21, 2023, at 4:30 p.m. ET during which management will review the Company’s financial results.
HealthEquity Fourth Quarter and Fiscal Year End 2023 Results Conference Call | |
Date: | March 21, 2023 |
Time: | 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time |
Dial-in: | 1-833-630-1956 (toll free); 1-412-317-1837 (international) |
Conference ID: | HealthEquity, Inc. call |
Webcast: | ir.healthequity.com |
The Company also announced that its management team plans to virtually present and meet with investors at the following upcoming investor conference:
KeyBanc Virtual Life Sciences & MedTech Investor Forum | |
Date: | March 22, 2023 |
Time: | 1:30 pm Eastern Time |
Webcast: | none |
About HealthEquity
HealthEquity is the leading provider of Health Savings Accounts (HSAs) and other consumer-directed benefits for nearly 15 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to connect health and wealth and value our culture of remarkable “Purple” service. For more information, visit www.healthequity.com.
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.
Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:
For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2022 and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Relations Contact:
Richard Putnam
801-231-0697
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$98.98 |
Daily Change: | 3.28 3.43 |
Daily Volume: | 1,262,237 |
Market Cap: | US$8.640B |
November 12, 2024 October 15, 2024 September 03, 2024 September 03, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB